Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Do analysts prefer SUPN or JAZZ?

Supernus Pharmaceuticals currently has a consensus price target of $36.00, indicating a potential upside of 14.83%. Jazz Pharmaceuticals has a consensus price target of $187.71, indicating a potential upside of 72.25%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Does the MarketBeat Community favor SUPN or JAZZ?

Jazz Pharmaceuticals received 656 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. Likewise, 80.87% of users gave Jazz Pharmaceuticals an outperform vote while only 73.10% of users gave Supernus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Supernus Pharmaceuticals	Outperform Votes 481 73.10%	Underperform Votes 177 26.90%
Jazz Pharmaceuticals	Outperform Votes 1137 80.87%	Underperform Votes 269 19.13%

Do insiders & institutionals have more ownership in SUPN or JAZZ?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 9.3% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings & valuation, SUPN or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$661.82M	2.64	$1.32M	$1.32	23.75
Jazz Pharmaceuticals	$4.07B	1.63	$414.83M	$8.79	12.40

Which has more volatility and risk, SUPN or JAZZ?

Supernus Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Does the media refer more to SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 13 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.28 beat Supernus Pharmaceuticals' score of 0.90 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SUPN or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of 11.60% compared to Supernus Pharmaceuticals' net margin of 9.16%. Jazz Pharmaceuticals' return on equity of 29.30% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	9.16%	7.79%	5.67%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 14 of the 18 factors compared between the two stocks.